{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T15:16:55Z","timestamp":1780327015164,"version":"3.54.1"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Sodium\u2013glucose cotransporter 2 inhibitors (SGLT2i) improve cardiovascular outcomes in chronic kidney disease, but their effects in peritoneal dialysis (PD) patients who are infection prone, remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study design<\/jats:title>\n                    <jats:p>The study design of this research is target-trial emulation using the global federated electronic health record database. Adults (18\u201390 years) with type 2 diabetes on PD for \u22653 months between February 2015 and June 2025 were included. Propensity score matching balanced SGLT2i and nonuser. Primary outcomes were all-cause mortality, severe sepsis, sepsis, and pneumonia; secondary outcomes included major adverse cardiovascular events (MACE) and PD-associated peritonitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 29\u00a0529 eligible patients, 2815 (9.5%) received SGLT2i. After matching, 2749 patients were retained in each group with well-balanced baseline characteristics. Over a median follow-up of 0.79 years, SGLT2i users were associated with lower risks of all-cause mortality [adjusted hazard ratio (aHR) 0.818], severe sepsis (aHR 0.802), sepsis (aHR 0.661), pneumonia (aHR 0.664), and PD-associated peritonitis (aHR 0.340). MACE was not significantly different (aHR 0.798). SGLT2i was not associated with increased diabetic ketoacidosis, hypoglycemia, genital infection, volume depletion, or amputation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this large real-world PD cohort with type 2 diabetes, SGLT2i use was associated with lower risks of death and major infections without safety concerns, supporting potential benefit pending randomized trial confirmation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ckj\/sfag148","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:46:14Z","timestamp":1778154374000},"source":"Crossref","is-referenced-by-count":0,"title":["Safety and clinical impact of SGLT2 inhibitor in patients undergoing peritoneal dialysis: a target-trial emulation study"],"prefix":"10.1093","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5020-3760","authenticated-orcid":false,"given":"Yi-Ting","family":"Chen","sequence":"first","affiliation":[{"name":"National Taiwan University Hospital Division of Nephrology, Department of Internal Medicine, , Taipei ,","place":["Taiwan"]},{"name":"National Taiwan University Hospital Division of Blood Purification, Department of Integrated Diagnostics & Therapeutics, , Taipei ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2537-9146","authenticated-orcid":false,"given":"Chung-An","family":"Wang","sequence":"additional","affiliation":[{"name":"Far Eastern Memorial Hospital Department of Medical Education, , New Taipei City ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1376-7780","authenticated-orcid":false,"given":"Jui-Yi","family":"Chen","sequence":"additional","affiliation":[{"name":"Chi-Mei Medical Center Division of Nephrology, Department of Internal Medicine, , Tainan ,","place":["Taiwan"]},{"name":"Chia Nan University of Pharmacy and Science Department of Health and Nutrition, , Tainan ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7935-0991","authenticated-orcid":false,"given":"Vin-Cent","family":"Wu","sequence":"additional","affiliation":[{"name":"National Taiwan University Hospital Division of Nephrology, Department of Internal Medicine, , Taipei ,","place":["Taiwan"]},{"name":"NSARF (National Taiwan University Hospital Study Group of ARF), TAIPAI, (Taiwan Primary Aldosteronism Investigators), and Division of Nephrology, Primary Aldosteronism Center (PAC) of Internal Medicine, National Taiwan University Hospital , Taipei ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"2026060110471546600_bib1","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41581-022-00535-6","article-title":"Kidney and heart failure outcomes associated with SGLT2 inhibitor use","volume":"18","author":"van\u00a0der\u00a0Aart-van\u00a0der\u00a0Beek","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"2026060110471546600_bib2","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2215\/CJN.09380822","article-title":"Kidney-protective effects of SGLT2 inhibitors","volume":"18","author":"Palmer","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026060110471546600_bib3","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control","volume":"17","author":"Cowie","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"2026060110471546600_bib4","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","article-title":"Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review","volume":"75","author":"Zelniker","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026060110471546600_bib5","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","article-title":"Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026060110471546600_bib6","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/s12882-023-03339-3","article-title":"UK Kidney Association clinical practice guideline: sodium-glucose co-transporter-2 (SGLT-2) inhibition in adults with kidney disease 2023 update","volume":"24","author":"Roddick","year":"2023","journal-title":"BMC Nephrol"},{"key":"2026060110471546600_bib7","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"Kidney Disease: Improving Global Outcomes CKDWG. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"2026060110471546600_bib8","article-title":"FARXIGA\u00ae (dapagliflozin) tablets, for oral use","author":"U.S. Food and Drug Administration"},{"key":"2026060110471546600_bib9","author":"European Medicines Agency","journal-title":"Dapagliflozin Viatris: EPAR\u2014Product Information"},{"key":"2026060110471546600_bib10","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s11906-024-01314-3","article-title":"Is there a role for SGLT2 inhibitors in patients with end-stage kidney disease?","volume":"26","author":"Siddiqui","year":"2024","journal-title":"Curr Hypertens Rep"},{"key":"2026060110471546600_bib11","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/s12933-024-02424-7","article-title":"Exploring the mortality and cardiovascular outcomes with SGLT-2 inhibitors in patients with T2DM at dialysis commencement: a health global federated network analysis","volume":"23","author":"Wang","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"2026060110471546600_bib12","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.2215\/CJN.0000000000000196","article-title":"Pharmacokinetic properties of dapagliflozin in hemodialysis and peritoneal dialysis patients","volume":"18","author":"Barreto","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026060110471546600_bib13","doi-asserted-by":"publisher","first-page":"sfaf350","DOI":"10.1093\/ckj\/sfaf350","article-title":"SGLT2 inhibitors in hemodialysis or peritoneal dialysis patients: rationale and state-of-the art","volume":"19","author":"Minutolo","year":"2026","journal-title":"Clin Kidney J"},{"key":"2026060110471546600_bib14","doi-asserted-by":"publisher","first-page":"101367","DOI":"10.1016\/j.diabet.2022.101367","article-title":"Risk of sepsis and pneumonia in patients initiated on SGLT2 inhibitors and DPP-4 inhibitors","volume":"48","author":"Wu","year":"2022","journal-title":"Diabetes Metab"},{"key":"2026060110471546600_bib15","doi-asserted-by":"publisher","first-page":"e22078","DOI":"10.1096\/fj.202100909RR","article-title":"SGLT2 inhibitor counteracts NLRP3 inflammasome via tubular metabolite itaconate in fibrosis kidney","volume":"36","author":"Ke","year":"2022","journal-title":"FASEB J"},{"key":"2026060110471546600_bib16","doi-asserted-by":"publisher","first-page":"e1719","DOI":"10.1210\/clinem\/dgab818","article-title":"Association between SGLT2 inhibitors vs DPP-4 inhibitors and risk of pneumonia among patients with type 2 diabetes","volume":"107","author":"Au","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026060110471546600_bib17","doi-asserted-by":"publisher","first-page":"e0286579","DOI":"10.1371\/journal.pone.0286579","article-title":"Severe infections in peritoneal dialysis and home hemodialysis patients: an inception cohort study","volume":"18","author":"Bitar","year":"2023","journal-title":"PLoS One"},{"key":"2026060110471546600_bib18","doi-asserted-by":"publisher","first-page":"1236404","DOI":"10.3389\/fendo.2023.1236404","article-title":"Cardiovascular outcomes and safety of SGLT2 inhibitors in chronic kidney disease patients","volume":"14","author":"Chen","year":"2023","journal-title":"Front Endocrinol"},{"key":"2026060110471546600_bib19","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/j.kint.2024.03.019","article-title":"Kidney protective mechanisms of SGLT2 inhibitors: evidence for a hemodynamic effect","volume":"105","author":"Yau","year":"2024","journal-title":"Kidney Int"},{"key":"2026060110471546600_bib20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/9944880","article-title":"Anti-inflammatory effects of empagliflozin and gemigliptin on LPS-stimulated macrophage via the IKK\/NF-\u03baB, MKK7\/JNK, and JAK2\/STAT1 signalling pathways","volume":"2021","author":"Lee","year":"2021","journal-title":"J Immunol Res"},{"key":"2026060110471546600_bib21","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.2174\/1381612828666220617153331","article-title":"Sodium-glucose cotransporter type 2 inhibitors: a new insight into the molecular mechanisms of diabetic nephropathy","volume":"28","author":"Li","year":"2022","journal-title":"Curr Pharm Des"},{"key":"2026060110471546600_bib22","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12933-023-01816-5","article-title":"Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms","volume":"22","author":"Huang","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"2026060110471546600_bib23","doi-asserted-by":"publisher","first-page":"1516126","DOI":"10.3389\/fphar.2025.1516126","article-title":"A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX","volume":"16","author":"Ludwig","year":"2025","journal-title":"Front Pharmacol"},{"key":"2026060110471546600_bib24","doi-asserted-by":"publisher","first-page":"24","DOI":"10.71079\/ASIDE.IM.03222516","article-title":"TriNetX and real-world evidence: a critical review of its strengths, limitations, and bias considerations in clinical research","volume":"1","author":"Nassar","year":"2025","journal-title":"ASIDE Int Med"},{"key":"2026060110471546600_bib25","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1002\/pds.5649","article-title":"Evaluating the use of methods to mitigate bias from non-transient medications in the case-crossover design: a systematic review","volume":"32","author":"Huang","year":"2023","journal-title":"Pharmacoepidemiol Drug Safe"},{"key":"2026060110471546600_bib26","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1111\/dom.14801","article-title":"Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: a systematic review and network meta-analysis","volume":"24","author":"Yang","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"2026060110471546600_bib27","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1097\/CCM.0000000000005869","article-title":"Risk of ICU admission and related mortality in patients with sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase-4 inhibitors: a territory-wide retrospective cohort study","volume":"51","author":"Ng","year":"2023","journal-title":"Crit Care Med"},{"key":"2026060110471546600_bib28","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.2215\/CJN.17621120","article-title":"Euglycemic ketoacidosis as a complication of SGLT2 inhibitor therapy","volume":"16","author":"Palmer","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026060110471546600_bib29","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s12350-019-01624-z","article-title":"Landmark analysis: a primer","volume":"26","author":"Morgan","year":"2019","journal-title":"J Nucl Cardiol"},{"key":"2026060110471546600_bib30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"The Lancet"},{"key":"2026060110471546600_bib31","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2026060110471546600_bib32","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2026060110471546600_bib33","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s40265-019-1057-0","article-title":"Emerging role of SGLT-2 inhibitors for the treatment of obesity","volume":"79","author":"Pereira","year":"2019","journal-title":"Drugs"},{"key":"2026060110471546600_bib34","doi-asserted-by":"publisher","first-page":"11795468251347777","DOI":"10.1177\/11795468251347777","article-title":"Evaluating the safety and efficacy of SGLT-2 inhibitors on reducing cardiovascular and renal mortality, morbidity and inflammatory outcomes in various patient populations: a systematic review and meta-analysis of 92 920 patients","volume":"19","author":"Haider","year":"2025","journal-title":"Clin Med Insights Cardiol"},{"key":"2026060110471546600_bib35","doi-asserted-by":"publisher","first-page":"4775","DOI":"10.2147\/DDDT.S269514","article-title":"SGLT2 inhibitors: a novel player in the treatment and prevention of diabetic cardiomyopathy","volume":"14","author":"Li","year":"2020","journal-title":"Drug Des Devel Ther"},{"key":"2026060110471546600_bib36","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1186\/s13054-025-05685-0","article-title":"Association between SGLT2 inhibitor use and risk of sepsis-induced cardiomyopathy in patients with type 2 diabetes: a propensity-matched cohort study","volume":"29","author":"Wu","year":"2025","journal-title":"Crit Care"},{"key":"2026060110471546600_bib37","doi-asserted-by":"publisher","first-page":"5634","DOI":"10.3390\/ijms23105634","article-title":"Role of sodium-glucose co-transporter 2 inhibitors in the regulation of inflammatory processes in animal models","volume":"23","author":"Feijoo-Bandin","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026060110471546600_bib38","doi-asserted-by":"publisher","first-page":"13700","DOI":"10.1038\/s41598-021-93156-1","article-title":"Canagliflozin protects against sepsis capillary leak syndrome by activating endothelial alpha1AMPK","volume":"11","author":"Ange","year":"2021","journal-title":"Sci Rep"},{"key":"2026060110471546600_bib39","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.2147\/DDDT.S360348","article-title":"Anti-hyperglycemic agents in the adjuvant treatment of sepsis: improving intestinal barrier function","volume":"16","author":"Wang","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"2026060110471546600_bib40","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1681\/ASN.2008020211","article-title":"Cyclooxygenase-2 mediates dialysate-induced alterations of the peritoneal membrane","volume":"20","author":"Aroeira","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2026060110471546600_bib41","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1161\/CIRCULATIONAHA.121.053350","article-title":"Cardiac late sodium channel current is a molecular target for the sodium\/glucose cotransporter 2 inhibitor empagliflozin","volume":"143","author":"Philippaert","year":"2021","journal-title":"Circulation"},{"key":"2026060110471546600_bib42","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1093\/bja\/aex234","article-title":"Epidemiology of sepsis and septic shock in critical care units: comparison between sepsis-2 and sepsis-3 populations using a national critical care database","volume":"119","author":"Shankar-Hari","year":"2017","journal-title":"Br J Anaesth"},{"key":"2026060110471546600_bib43","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1097\/CCM.0000000000004449","article-title":"A comparison of Sepsis-2 (systemic inflammatory response syndrome based) to Sepsis-3 (sequential organ failure assessment based) definitions\u2014a multicenter retrospective study","volume":"48","author":"Engoren","year":"2020","journal-title":"Crit Care Med"},{"key":"2026060110471546600_bib44","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ekir.2025.09.049","article-title":"Empagliflozin and ultrafiltration volume in patients undergoing peritoneal dialysis","volume":"11","author":"Doi","year":"2026","journal-title":"Kidney Int Rep"},{"key":"2026060110471546600_bib45","doi-asserted-by":"publisher","first-page":"20543581241293500","DOI":"10.1177\/20543581241293500","article-title":"Role of SGLT-2 inhibitors in ultrafiltration failure in peritoneal dialysis: a narrative review","volume":"11","author":"Riedl\u00a0Khursigara","year":"2024","journal-title":"Can J Kidney Health Dis"},{"key":"2026060110471546600_bib46","doi-asserted-by":"publisher","first-page":"101619","DOI":"10.1016\/j.eclinm.2022.101619","article-title":"Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population: a retrospective cohort study from the TriNetX US collaborative networks","volume":"53","author":"Wang","year":"2022","journal-title":"EClinicalMedicine"},{"key":"2026060110471546600_bib47","doi-asserted-by":"publisher","first-page":"e2350050","DOI":"10.1001\/jamanetworkopen.2023.50050","article-title":"Sodium-glucose cotransport protein 2 inhibitors in patients with type 2 diabetes and acute kidney disease","volume":"7","author":"Pan","year":"2024","journal-title":"JAMA Netw Open"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfag148\/68247003\/sfag148.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/6\/sfag148\/68247003\/sfag148.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/6\/sfag148\/68247003\/sfag148.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T14:47:23Z","timestamp":1780325243000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfag148\/8672569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfag148","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,5,7]]},"article-number":"sfag148"}}